GlassScriptPhysician profile
Marc Rubinstein
NPI 1821092800
$2,367.40
in general payments reported to CMS, 2019-2025
23 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.66 · 2020: $99.60 · 2021: $197 · 2022: $77.51 · 2023: $215 · 2024: $925 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.84 | 2022-2025 | Lumigan, Durysta |
| Alcon Vision LLC | $334.65 | 2024-2025 | Rhopressa, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $237.73 | 2021-2025 | Cequa |
| Glaukos Corporation | $221.21 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Rxsight INC | $189.98 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Harrow Eye, LLC | $126.05 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $96.45 | 2025 | Xdemvy |
| Allergan, INC. | $75.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $73.28 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $68.46 | 2025 | Iluvien, Purified Cortrophin Gel |
| Amgen INC. | $65.91 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $60.17 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $53.45 | 2023-2025 | Syfovre |
| Oyster Point Pharma, INC. | $50.05 | 2023-2024 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $39.13 | 2024 | Miebo |
| Sight Sciences, INC. | $37.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.90 | 2021 | |
| Dompe US, INC. | $27.61 | 2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $24.92 | 2024 | Eylea Hd, Eylea |
| Sanofi-Aventis U.S. LLC | $24.60 | 2020 | |
| Genzyme Corporation | $22.84 | 2019 | |
| Genentech USA, INC. | $18.92 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.